Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Stefan Aebi et al.|The Lancet Oncology|2017Cited by 122
P42 The age-related ER+PR+ expression differs by HER-2/neu statusHongYun Huang, Marie-Rose Christiaens, P. Neven et al.|The Breast|2005Cited by 0